glp 1 fda compounding alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products FDA Ban on Compounded GLP-1

, - , , 10001500

Barayeu, U

A total of 456 patients were studied: 379 (83.1%) were White, 47 (10.3%) were Hispanic or Latino, 25 (5.5%) were East Asian, 3 (0.7%) were Black or African American, and 2 (0.4%) were of West Asian ethnicity

in: PubMed | Google Scholar 1 Department of Pediatrics, Division of Genetic and Genomic Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

When the two groups were analyzed side by side, a clear pattern emerged: those taking GLP-1 medications had up to a 29% higher risk of developing a chronic cough during the first five years of treatment

But when a company omits a known danger to them that could hurt people, theyre lying to us